Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis.
adverse events
biological disease-modifying anti-rheumatic drugs
effectiveness
late onset rheumatoid arthritis
older age
rheumatoid arthritis
safety
Journal
Canadian geriatrics journal : CGJ
ISSN: 1925-8348
Titre abrégé: Can Geriatr J
Pays: Canada
ID NLM: 101579189
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
6
2020
Statut:
epublish
Résumé
Biological disease-modifying antirheumatic drugs (bDMARDs) are recommended for rheumatoid arthritis (RA), but older patients reportedly experience more adverse events (AEs) and show variable treatment response. The objective of this study was to evaluate AEs and effectiveness of bDMARDs in a cohort of older patients. AE and treatment effectiveness (based on DAS28 scores) data from a prospective provincial pharmacovigilance program for the years 2006-2009 in patients 55-64, 65-74, and 75+ years of age were compared. An intention to treat analysis with chi-square and unpaired There were a total of 333 patients (156 were aged 55-64, 125 were 65-74, 52 were 75+). Those 75+ had higher disease activity and worse functional status at baseline. Among those 75+, AEs with bDMARDs were more common and likely to lead to discontinuation of therapy, be graded as severe, and classified as infectious ( Patients 75+ treated with bDMARDs are at a significantly greater risk of AEs, including infectious ones. The higher remission found in the oldest age group warrants further study.
Sections du résumé
BACKGROUND
BACKGROUND
Biological disease-modifying antirheumatic drugs (bDMARDs) are recommended for rheumatoid arthritis (RA), but older patients reportedly experience more adverse events (AEs) and show variable treatment response. The objective of this study was to evaluate AEs and effectiveness of bDMARDs in a cohort of older patients.
METHODS
METHODS
AE and treatment effectiveness (based on DAS28 scores) data from a prospective provincial pharmacovigilance program for the years 2006-2009 in patients 55-64, 65-74, and 75+ years of age were compared. An intention to treat analysis with chi-square and unpaired
RESULTS
RESULTS
There were a total of 333 patients (156 were aged 55-64, 125 were 65-74, 52 were 75+). Those 75+ had higher disease activity and worse functional status at baseline. Among those 75+, AEs with bDMARDs were more common and likely to lead to discontinuation of therapy, be graded as severe, and classified as infectious (
CONCLUSION
CONCLUSIONS
Patients 75+ treated with bDMARDs are at a significantly greater risk of AEs, including infectious ones. The higher remission found in the oldest age group warrants further study.
Identifiants
pubmed: 32494334
doi: 10.5770/cgj.23.393
pii: cgj-23-184
pmc: PMC7259924
doi:
Types de publication
Journal Article
Langues
eng
Pagination
184-189Informations de copyright
© 2020 Author(s). Published by the Canadian Geriatrics Society.
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST DISCLOSURES The authors declare that no conflicts of interest exist.
Références
Arthritis Rheum. 2011 Mar;63(3):633-9
pubmed: 21360492
Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S39-43
pubmed: 15552513
Arthritis Care Res (Hoboken). 2014 Sep;66(9):1289-95
pubmed: 25299001
Ann Rheum Dis. 2014 Mar;73(3):529-35
pubmed: 24401994
Drugs Aging. 2016 Feb;33(2):97-107
pubmed: 26833350
Joint Bone Spine. 2015 Jan;82(1):25-30
pubmed: 25241333
Semin Arthritis Rheum. 2019 Apr;48(5):799-807
pubmed: 30185379
J Rheumatol. 2003 Jan;30(1):167-78
pubmed: 12508408
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Joint Bone Spine. 2015 May;82(3):154-60
pubmed: 25553833
Ann Rheum Dis. 2013 Oct;72(10):1664-8
pubmed: 23117244
Arthritis Rheum. 2010 Jan;62(1):22-32
pubmed: 20039405
Rheumatol Int. 2012 Jun;32(6):1511-9
pubmed: 21327436
Rev Bras Reumatol Engl Ed. 2017 Sep - Oct;57(5):491-494
pubmed: 29037323
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S4-13
pubmed: 22588760
Rheumatology (Oxford). 2014 Apr;53(4):671-7
pubmed: 24352338
Clin Rev Allergy Immunol. 2010 Apr;38(2-3):90-6
pubmed: 19548124
Clin Rheumatol. 2012 Feb;31(2):211-7
pubmed: 21720763
J Rheumatol. 2007 Jun;34(6):1401-14
pubmed: 17552067
Arthritis Rheumatol. 2016 Jan;68(1):1-26
pubmed: 26545940
Arthritis Rheum. 2008 Jan 15;59(1):32-41
pubmed: 18163417
Rheumatology (Oxford). 2005 May;44(5):695-6
pubmed: 15705631
Rheumatology (Oxford). 2011 Nov;50(11):1999-2004
pubmed: 21856725
Ann Rheum Dis. 2009 Sep;68(9):1470-3
pubmed: 19015210
Health Qual Life Outcomes. 2003 Jun 09;1:20
pubmed: 12831398